---
title: Antiemetics
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 10
date: 2023-03-30
---


- Nausea Causing Medications
  - Aspirin, NSAIDs, Opioids
  - Erythromycin, sulfonamides, Acyclovir
  - Antiarrhythmics, Antihypertensives, Digoxin, Diuretics
  - Contraception, Antidiabetic meds
  - Anticonvulsants, Parkinson's Disease meds
  - W/U: Residuals
- Selective 5-HT3 Antagonist
  - MOA: Block serotonin receptors in the CNS and GI
    - Works on GI tract primarily, but CNS/PNS also
    - Used in gastroenteritis
    - SE: Headache, constipation, diarrhea, dry mouth, fatigue, Serotonin Syndrome, QTc Prolongation
    - CI: PKU, Hepatic Impairment
  - Ondansetron (Zofran)
    - Dose: 4-8mg Oral, Sublingual, IV over 15 minutes
    - SE: QTc Prolongation, Activating
  - Palonosetron (Aloxi)
    - Dose: 0.25mg IV
    - No QT prolongation, 40 hour half life, better than 8mg zofran
    - SE: Activating
  - Dolasetron
  - Granisetron
    - Oral, IV, Subcutaneous, Transdermal
- Histamine (H1) Receptor Antagonists
  - Notes:
    - Works on CNS (area postrema) and in the vestibular nucleus
    - SE: QTc Prolongation
  - Diphenhydramine (Benadryl)
    - 10-50mg per dose, up to 100mg per dose, 400mg per day
    - Oral, IV, IM
    - SE: QTc Prolongation
    - CI: Acute asthma, GI obstruction, Closed angle glaucoma
  - Meclizine
    - No QTc prolongation
  - Dimenhydrinate
    - No QTc prolongation
  - Cyclizine
  - Mirtazapine (Remeron)
  - Hydroxyzine (Vistaril)
    - Quick acting, short-term, anxiolytic, insomnia
    - SE: sedation, dry mouth, constipation, urinary retention, blurry vision
      - QTc Prolongation
- Phenothiazine
  - Prochlorperazine (Compazine)
    - MOA: D2 antagonism ≥ H1 = M1
    - Dose: 10mg IV
    - Little to no QTc prolongation
    - SE: Extrapyramidal SE, M1 activity
  - Chlorpromazine (Thorazine)
    - MOA: D2 = H1 ≥ M1 ≥ 5HT3
    - Dose: 25mg IV/IM
    - SE: Extrapyramidal SE, QTc Prolongation, M1 activity
  - Promethazine (Phenergan)
    - MOA: H1 ≥ M1 ≥ D2
    - Dose: 12.5-25mg PO/IM
    - SE: Extrapyramidal SE, QTc Prolongation, Most M1 activity
- Butyrophenone
  - Droperidol
    - MOA: D2 Antagonism ≥≥≥ H1
    - Dose: 0.625-2.5 IV, IM
    - SE: QTc Prolongation
  - Haloperidol
    - MOA: D2 Antagonism ≥≥≥ H1
    - Dose: 2-5 mg IV, Oral, IM
    - SE: QTc Prolongation
- Benzamide
  - Metoclopramide
    - MOA: D2 ≥ 5-H3T antagonism, Cholinergic Agonism
    - 10-20mg Oral, IV, IM
    - SE: QTc Prolongation
  - Domperidone
    - MOA: D2 antagonism
    - Oral
    - SE: QTc Prolongation, Headache, Xerostomia
- Antimuscarinic
  - MOA: M1 antagonism
  - Scopolamine
    - Transdermal
    - No QTc Prolongation
    - SE: Xerostomia, Blurry Vision, Fatigue
- Benzodiazepines
  - GABA-A Agonism
  - SE: Anterograde amnesia
  - No QTc Prolongation
  - Lorazepam
    - Oral, Sublingual, IV, IM
  - Alprazolam
    - Oral
- Glucocorticoid
  - Dexamethasone (Decadron)
  - No QTc prolongation
- Neurokinin Receptor Antagonists
  - MOA: NK1 Antagonism
  - No QTc Prolongation
  - Aprepitant
    - Oral
    - SE: CYP3A4 Inhibitor, fatigue, Neutropenia (≥ in children)
  - Fosaprepitant
    - IV
    - SE: CYP3A4 Inhibitor, fatigue, Neutropenia (≥ in children)
  - Netupitant
    - SE: CYP3A4 Inhibitor, fatigue, Neutropenia (≥ in children)
  - Rolapitant
    - SE: CYP2D5 inhibitor, Dizziness
- Dopamine Antagonists
  - SE: muscle spasms, restlessness
  - Olanzapine (Zyprexa)
- Appetite Stimulants (Orexigenic)
  - Dronabinol
  - Mirtazapine (Remeron)
  - Prednisone
  - Megestrol
  - Lithium
  - Insulin